Six stocks receive buy upgrades from major firms, citing low expectations, strong earnings, and undervalued upside.
Guggenheim upgraded StubHub to Buy with a $12.50 price target, up from $8.50, citing 30% potential upside after the company reset Street expectations for this year and next. The firm noted the bar is now “extremely low” on direct issuance and advertising, suggesting any progress could drive gains.
UBS raised Jazz Pharmaceuticals to Buy with a $307 target, up from $188, due to improved confidence in its base business and Ziihera’s commercial potential. Bernstein upgraded American Tower to Outperform, while Canaccord and HSBC also issued buy upgrades for Progyny and Credicorp, respectively, highlighting strong Q1 results and conservative guidance.
The upgrades reflect a broader shift in sentiment toward stocks with undervalued growth prospects or beaten-down expectations, though market reaction remains pending.